Biotech announced that the company received a notice from the European Medicines Agency and that Usymro® received positive opinions from the EMA Human Medicines Commission. The CHMP recommended that the European Commission approve the marketing of usyMRO® for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn's disease in adults and children. The drug has been commercialized in many regions around the world, including the United States, Russia, Brazil, the European Union, the United Kingdom, Switzerland, Australia and other regions. BAT2206 was approved for listing by the US FDA in May 2025 and submitted a marketing license application to the Chinese NMPA. Receiving positive feedback from CHMP this time is expected to expand the company's international market, enhance the international influence of products, and have a positive impact on the company's long-term business performance.

Biotech announced that the company received a notice from the European Medicines Agency and that Usymro® received positive opinions from the EMA Human Medicines Commission. The CHMP recommended that the European Commission approve the marketing of usyMRO® for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn's disease in adults and children. The drug has been commercialized in many regions around the world, including the United States, Russia, Brazil, the European Union, the United Kingdom, Switzerland, Australia and other regions. BAT2206 was approved for listing by the US FDA in May 2025 and submitted a marketing license application to the Chinese NMPA. Receiving positive feedback from CHMP this time is expected to expand the company's international market, enhance the international influence of products, and have a positive impact on the company's long-term business performance.